Renin Profiling in Selection of Initial Antihypertensive Drug

NACompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Hypertension
Interventions
DRUG

olmesartan, hydrochlorothiazide, amlodipine

hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg

DRUG

hydrochlorothiazide (HCTZ) or olmesartan

HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added

Trial Locations (5)

10451

Lincoln Medical and Mental Health Center, The Bronx

10461

Albert Einstein College of Medicine - GCRC, The Bronx

Jacobi Medical Center, The Bronx

10467

Bronx Nephrology Hypertension, PC, The Bronx

Ralph Yung, MD, The Bronx

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

The Louis & Rachel Rudin Foundation

OTHER

NCT00834600 - Renin Profiling in Selection of Initial Antihypertensive Drug | Biotech Hunter | Biotech Hunter